Home » Stocks » VYGR

Voyager Therapeutics, Inc. (VYGR)

Stock Price: $5.57 USD 0.04 (0.72%)
Updated Mar 8, 2021 2:06 PM EST - Market open
Market Cap 208.23M
Revenue (ttm) 171.13M
Net Income (ttm) 36.74M
Shares Out 37.13M
EPS (ttm) 0.98
PE Ratio 5.68
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $5.57
Previous Close $5.53
Change ($) 0.04
Change (%) 0.72%
Day's Open 5.59
Day's Range 5.40 - 5.73
Day's Volume 327,312
52-Week Range 5.18 - 14.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Newsfile Corp - 1 day ago

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDA...

GlobeNewsWire - 4 days ago

LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021 LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021

Newsfile Corp - 4 days ago

New York, New York--(Newsfile Corp. - March 3, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR)...

PRNewsWire - 5 days ago

NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and ce...

GlobeNewsWire - 1 week ago

NEW YORK, Feb. 27, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between Ju...

24/7 Wall Street - 1 week ago

With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.

Other stocks mentioned: ABNB, EDIT, CNP, AGIO, DNLI, PTR, TREE, ZYXI
PRNewsWire - 1 week ago

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients...

PRNewsWire - 1 week ago

LOS ANGELES, Feb. 25, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc....

Business Wire - 1 week ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NAS...

GlobeNewsWire - 1 week ago

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between Ju...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (N...

GlobeNewsWire - 2 weeks ago

LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021 LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021

GlobeNewsWire - 2 weeks ago

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: V...

GlobeNewsWire - 2 weeks ago

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) from Ju...

PRNewsWire - 2 weeks ago

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and ce...

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe n...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: V...

PRNewsWire - 2 weeks ago

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("V...

GlobeNewsWire - 2 weeks ago

NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of   Voyager Therapeutics, Inc. (NASDAQ: VYGR) betwe...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (N...

Business Wire - 2 weeks ago

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VYGR #ClassAction--Shareholder rights law firm Robbins LLP reminds shareholders that a purchaser of Voyager Therapeutics, Inc. (Nasdaq: VYGR)...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - February 10, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (N...

Newsfile Corp - 3 weeks ago

Los Angeles, California--(Newsfile Corp. - February 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyag...

GlobeNewsWire - 3 weeks ago

Investors with losses are encouraged to contact the firm before March 24, 2021; click here to submit trade information

GlobeNewsWire - 3 weeks ago

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between...

PRNewsWire - 1 month ago

NEW YORK, Feb. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - February 6, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NA...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and No...

GlobeNewsWire - 1 month ago

NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutic...

PRNewsWire - 1 month ago

NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therap...

GlobeNewsWire - 1 month ago

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) from Ju...

Benzinga - 1 month ago

Voyager Therapeutics (NASDAQ: VYGR) shares are trading lower Wednesday after the company announced that the FDA had notified Neurocrine that it placed a clinical hold on the RESTORE-1 clinical...

Other stocks mentioned: BCRX, OCGN
Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NAS...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of...

PRNewsWire - 1 month ago

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Voya...

GlobeNewsWire - 1 month ago

LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021 LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021

Zacks Investment Research - 1 month ago

As of late, it has definitely been a great time to be an investor in Voyager Therapeutics (VYGR).

PRNewsWire - 1 month ago

LOS ANGELES, Jan. 27, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc....

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $VYGR #VYGR--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc.

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - January 26, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NA...

GlobeNewsWire - 1 month ago

NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASD...

Newsfile Corp - 1 month ago

Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Voyager Therapeutics, Inc...

Business Wire - 1 month ago

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VYGR #ClassAction--Voyager Therapeutics, Inc. (VYGR) Misled Shareholders Regarding the Viability of its Lead Clinical Candidate for Huntingto...

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $VYGR #VYGR--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc.

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Voyager Therapeutics, ...

PRNewsWire - 1 month ago

NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and ce...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe n...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Voyager (VYGR) stock based on the movements in the options market lately.

About VYGR

Voyager Therapeutics, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progr... [Read more...]

Industry
Biotechnology
IPO Date
Nov 11, 2015
CEO
G. Andre Turenne
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
VYGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is 10.25, which is an increase of 84.02% from the latest price.

Price Target
$10.25
(84.02% upside)
Analyst Consensus: Buy